TD Private Client Wealth LLC Sells 17,777 Shares of Edwards Lifesciences Co. (NYSE:EW)

TD Private Client Wealth LLC reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 84.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,346 shares of the medical research company's stock after selling 17,777 shares during the period. TD Private Client Wealth LLC's holdings in Edwards Lifesciences were worth $221,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Stableford Capital II LLC raised its holdings in Edwards Lifesciences by 2.7% during the second quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company's stock worth $533,000 after acquiring an additional 159 shares in the last quarter. Purus Wealth Management LLC raised its holdings in shares of Edwards Lifesciences by 5.2% in the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company's stock valued at $297,000 after purchasing an additional 160 shares during the period. Busey Bank lifted its stake in Edwards Lifesciences by 1.9% in the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company's stock valued at $816,000 after purchasing an additional 165 shares during the last quarter. Commerzbank Aktiengesellschaft FI increased its position in Edwards Lifesciences by 7.4% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 2,415 shares of the medical research company's stock worth $224,000 after buying an additional 166 shares during the last quarter. Finally, JFS Wealth Advisors LLC raised its stake in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after buying an additional 166 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Down 0.9 %

Edwards Lifesciences stock traded down $0.65 during mid-day trading on Friday, reaching $73.32. The stock had a trading volume of 3,092,539 shares, compared to its average volume of 4,642,550. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock's 50-day simple moving average is $69.42 and its 200-day simple moving average is $73.99. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $43.24 billion, a PE ratio of 10.58, a price-to-earnings-growth ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts' consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business's quarterly revenue was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $0.59 earnings per share. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at $3,262,521.36. The trade was a 9.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now directly owns 198,526 shares of the company's stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock worth $2,323,150 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Citigroup boosted their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday. Truist Financial reiterated a "hold" rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. The Goldman Sachs Group boosted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, December 5th. Wells Fargo & Company reduced their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an "overweight" rating on the stock in a research note on Monday, September 9th. Finally, Piper Sandler lowered their target price on Edwards Lifesciences from $73.00 to $70.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $78.65.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.